Director Denice Torres filed a Form 4 with the SEC on November 4, 2026, disclosing a purchase of 5,000 shares of Seaport Therapeutics, Inc. common stock on November 3, 2026.

Key Highlights

  • Reporting person: Denice Torres, identified as a Director of Seaport Therapeutics, Inc.
  • Transaction: Purchase (transaction code P) of 5,000 shares of common stock on November 3, 2026.
  • Price per share: $19.865, as reported in the filing.
  • Direct ownership following transaction: 5,000 shares held directly.
  • Indirect ownership: 13,406 shares held indirectly by the Denice M. Torres Revocable Trust.
  • Disclaimer: Torres disclaims beneficial ownership of the trust shares for Section 16 purposes, except to the extent of her pecuniary interest, according to the filing.

Torres Open-Market Purchase of Seaport Therapeutics Common Stock

According to the Form 4 filed on November 4, 2026, Denice Torres, a Director at Seaport Therapeutics, Inc. (NASDAQ:SPTX), acquired 5,000 shares of the company's common stock on November 3, 2026, at a price of $19.865 per share. The transaction was coded as a purchase (P) and resulted in direct beneficial ownership of 5,000 shares following the reported transaction.

In addition to the directly held shares, the filing reports that Torres holds 13,406 shares of common stock indirectly through the Denice M. Torres Revocable Trust. With respect to those indirectly held shares, the filing states that Torres "disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act, except to the extent of her pecuniary interest therein, if any," and that the report "shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."

No derivative securities transactions were reported in Table II of the filing. The Form 4 was signed by Lana Gladstein as Attorney-in-Fact on November 4, 2026, and was filed on behalf of Torres as an individual reporting person.

What Was Disclosed

The filing disclosed a director-level open-market purchase of 5,000 shares of Seaport Therapeutics common stock at $19.865 per share on November 3, 2026, plus indirect ownership of 13,406 shares held through the Denice M. Torres Revocable Trust.